Skip to main navigation
Skip to search
Skip to main content
Scholars @ UT Health San Antonio Home
Help & FAQ
English
Español
Home
Profiles
Research units
Publications
Datasets
Search by expertise, name or affiliation
Synopsis of angiogenesis inhibitors in oncology.
Lee M. Ellis
, Wenbiao Liu
, Fan Fan
, Young Do Jung
, Niels Reinmuth
, Oliver Stoeltzing
, Akihiko Takeda
, Morihisa Akagi
,
Alexander A. Parikh
, Syed Ahmad
Research output
:
Contribution to journal
›
Review article
›
peer-review
23
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Synopsis of angiogenesis inhibitors in oncology.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Angiogenesis Inhibitor
100%
Angiogenesis
66%
Combination Therapy
66%
Development
66%
Antiangiogenic
66%
Comprehension
66%
Angiogenic Factor
33%
Metastatic Carcinoma
33%
Biological Product
33%
Toxicity
33%
Tumor Progression
33%
Primary Tumor
33%
Prothrombin
33%
Antiangiogenic Activity
33%
Tumor Angiogenesis
33%
Antiangiogenic Therapy
33%
Tumor Regression
33%
Therapeutic Modality
33%
Introspection
33%
Survival Factor
33%
Survival
33%
Drive
33%
Oncology
33%
Pharmacology, Toxicology and Pharmaceutical Science
Angiogenesis Inhibitor
100%
Chemotherapy
66%
Cytotoxic Chemotherapy
66%
Angiogenic Factor
33%
Biological Product
33%
Metastasis
33%
Toxicity
33%
Primary Tumor
33%
Tumor Growth
33%
Prothrombin
33%
Tumor Regression
33%
Survival
33%
Survival Factor
33%